Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia

Current Medical Research and Opinion
Thomas M FileNeringa Zadeikis

Abstract

To evaluate the time to symptom resolution and i.v.-to-p.o. transition in community-acquired pneumonia (CAP) patients treated with 750 mg or 500 mg levofloxacin. A retrospective, subset analysis of a multicenter, randomized, double-blind, controlled trial comparing 750 mg levofloxacin for 5 days to 500 mg levofloxacin for 10 days for the treatment of CAP. A total of 528 CAP patients were included. Baseline symptoms were re-evaluated on Day 3 of therapy, and time to i.v.-to-p.o. transition was recorded for inpatients. For the overall population, 67.4% of patients receiving 750 mg levofloxacin had resolution of fever by Day 3 of therapy, compared to 54.6% of 500 mg treated patients (P = 0.006). Patients who started on 750 mg levofloxacin i.v. (N = 108) transitioned to p.o. in an average of 2.68 days while those starting on 500 mg i.v. (N = 124) transitioned in 2.95 days (P = 0.144). The median time for i.v.-to-p.o. switch was 2.35 days and 2.75 days for patients receiving 750 mg and 500 mg levofloxacin, respectively (P = 0.098, log rank test). By Day 3 of therapy, 68% of patients receiving the 750 mg dose had transitioned from i.v. to p.o. levofloxacin, compared with 61% of the 500 mg group (P = 0.280). The safety profiles were c...Continue Reading

References

May 1, 1995·Diagnostic Microbiology and Infectious Disease·J A Ramirez
Jan 23, 1997·The New England Journal of Medicine·M J FineW N Kapoor
Jun 1, 1999·The Journal of Antimicrobial Chemotherapy·F SevinçP Speelman
Dec 1, 2000·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·L C Clark, C W Davis
Jun 13, 2001·American Journal of Respiratory and Critical Care Medicine·M S NiedermanUNKNOWN American Thoracic Society
Nov 21, 2001·Pharmacotherapy·B W GundersonJ C Rotschafer
May 17, 2003·Clinical Therapeutics·Sanjay MerchantYa-Chen Tina Shih
Sep 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lala M DunbarJames B Kahn
Sep 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A Mandell, Thomas M File
Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN Infectious Diseases Society of America

❮ Previous
Next ❯

Citations

Jul 8, 2011·BMC Infectious Diseases·Christopher R FreiJeff R Schein
Jan 30, 2015·Journal of Biopharmaceutical Statistics·Jim X Xiang
Nov 23, 2006·The Medical Clinics of North America·Burke A Cunha
Dec 21, 2006·Diagnostic Microbiology and Infectious Disease·Jack B AnonJames B Kahn
Jul 5, 2005·The American Journal of Medicine·Ronald F GrossmanJames S Tan
May 19, 2012·Expert Opinion on Pharmacotherapy·Antoni Torres, Adamantia Liapikou
Jul 14, 2006·International Journal of Antimicrobial Agents·John E ConteElisabeth Zurlinden
Jul 4, 2018·Infection & chemotherapy·Mi Suk LeeSungmin Kiem
Sep 7, 2018·The Cochrane Database of Systematic Reviews·Jesús López-AlcaldeManuel Gómez-García
May 12, 2010·Expert Review of Anti-infective Therapy·Ayman M Noreddin, Walid F Elkhatib

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
L DunbarJames B Kahn
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
V ErardT Calandra
© 2021 Meta ULC. All rights reserved